Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 03 Jan 2024
As the second leading cause of death in the European Union in 2020, with 11.2 million deaths, cancer accounts for 23 percent of all deaths. The fact that 40% of these cancers could have been prevented makes the figure all the more tragic.
Read Full NewsPhase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.
Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years
Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism
1.
Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC
2.
Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy
3.
Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy
4.
Biocomputer From Human Neurons Plays Doom, Raises Ethics
5.
AI is useful in low-resource areas for triaging breast masses.
1.
Navigating the Complexity of Peritoneal Carcinomatosis: A Guide for Patients and Caregivers
2.
Clinical Perspectives in Oncology for Better Care
3.
The Different Types of Cysts and Why They Occur: Insights from a Dermatologist
4.
Emerging Therapies Using Immune-Engineered Cancer Eradication Platforms
5.
Radiomics-Based Prediction of Treatment Response in Cancer
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
Navigating the Complexities of Ph Negative ALL - Part XIII
5.
Innovations in Hematology
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge